Novavax

India’s hopes to administer two billion doses of Covid-19 vaccines between August and December have received a boost with a new US-made vaccine to be produced in India by the Serum Institute showing high protective efficacy. The US-based vaccine maker Novavax announced that its protein-based Covid-19 vaccine has demonstrated 90.4 per cent efficacy against the novel coronavirus infection and 100 per cent efficacy against moderate and severe disease. “Today, Novavax is one step closer to addressing the critical and persistent global health need for additional Covid-19 vaccines,” Stanley Erck, chief executive officer of Novavax, said in a statement. “These results…